Court Allows Sale of Vuse Menthol E-cigarette Pods

Mar.23.2023
Court Allows Sale of Vuse Menthol E-cigarette Pods
Vuse's mint-flavored products will continue to be sold in the US, despite FDA's refusal to approve them.

After the Fifth Circuit Court of Appeals in the United States issued a temporary stay on Monday, R.J. Reynolds Vapor is allowed to continue selling its Vuse products in two mint flavors that had been subject to a marketing denial order (MDO).


Last Friday, the US Food and Drug Administration (FDA) rejected R.J. Reynolds' PMTA for its Vuse alternative pod mint 4.8% (nicotine content) G1 and Vuse alternative pod mint 4.8% G2 tobacco products.


As a result, Renault will be prohibited from selling or distributing these products in the United States, or else it will face enforcement action from the US Food and Drug Administration. However, the appellate court's ruling allows these products to continue being sold in the market.


A similar incident occurred. In October of last year, the US Food and Drug Administration issued a marketing denial order (MDO) against several mint-flavored soda products sold by Logic Technology Development. This was the first time the FDA had issued an MDO against mint products after undergoing scientific review.


After several days, Logic Corporation obtained a court order from the U.S. Third Circuit Court of Appeals to temporarily suspend the order.


Related reading:


British American Tobacco seeks to halt FDA's marketing ban on two Vuse e-cigarette products.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Research Summary | NHANES Study: Smoking or E-Cigarette Use Linked to Higher Prevalence of Elevated Blood Pressure and Hypertension
Research Summary | NHANES Study: Smoking or E-Cigarette Use Linked to Higher Prevalence of Elevated Blood Pressure and Hypertension
A cross-sectional analysis based on the US NHANES 2021–2023 cycle, including 6,262 participants aged over 12, found that compared with people who neither smoke nor vape, those who smoke and/or use e-cigarettes had a higher prevalence of elevated blood pressure and hypertension. After full adjustment, smoking/vaping was associated with elevated blood pressure (aOR 1.34) and hypertension (aOR 1.46), and with a 1.05 mmHg higher diastolic blood pressure.
Feb.09 by 2FIRSTS.ai
Australia: NSW police and ABF seize illicit tobacco and vapes worth over A$1.6 million in Sydney’s southwest
Australia: NSW police and ABF seize illicit tobacco and vapes worth over A$1.6 million in Sydney’s southwest
In Australia’s New South Wales, a joint operation in Sydney’s southwest led to the seizure of illicit tobacco and vape products valued at over A$1.6 million (about US$1.09 million) from a warehouse in Riverwood.
Jan.22 by 2FIRSTS.ai
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11
KT&G Q4 and Full-Year 2025 Results: Global CC Strongest, NGP Penetration Expands
KT&G Q4 and Full-Year 2025 Results: Global CC Strongest, NGP Penetration Expands
According to KT&G’s official website (Feb 5, 2026), KT&G released its 2025 fourth-quarter and full-year results. Driven by strong growth in its overseas cigarette business and a rebound in its real estate business, the company posted double-digit increases in both revenue and operating profit, reaching record-high performance.
Feb.05 by 2FIRSTS.ai
UK Barnsley: Town-centre vape shop and owner hit with £15,000+ bill after ignoring three improvement notices
UK Barnsley: Town-centre vape shop and owner hit with £15,000+ bill after ignoring three improvement notices
A Barnsley town-centre vape retailer and its owner have been ordered to pay more than £15,000 after admitting multiple offences linked to the continued sale of illegal single-use vapes and non-compliant food items, despite three formal improvement notices.
Feb.06 by 2FIRSTS.ai
West Virginia Senate Backs Vape Tax Increase to Offset Income Tax Cut
West Virginia Senate Backs Vape Tax Increase to Offset Income Tax Cut
The West Virginia Senate approved a 10% personal income tax cut on February 22, 2026, with part of the revenue offset coming from increased excise taxes on vape and e-cigarette products.
News
Feb.23